FAM
CRVS icon

Fred Alger Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Fred Alger Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-144,381
Closed -$1.11M – 463
2025
Q4 		$1.11M Buy
+144,381
New +$1.14M ﹤0.01% 349

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fred Alger Management's CRVS Position: Q1 2026 in Review

Fred Alger Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 144,381 shares — an estimated $1.11M sold.

Fred Alger Management first reported a position in CRVS in Q4 2025 and held it in 1 quarter. The position peaked at $1.11M in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Fred Alger Management reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fred Alger Management sold 144,381 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
  • Fred Alger Management first reported a position in Corvus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Fred Alger Management's Corvus Pharmaceuticals position peaked at $1.11M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.